Strides Arcolab receives US FDA approval for Oxaliplatin injection

Onco Therapies, a wholly-owned subsidiary of Strides Arcolab, has received final ANDA approval for Oxaliplatin injection 50mg/10mL and 100mg/20mL. The company had received tentative approval from US FDA in November 2011 based on a para III filing. This approval was later converted to a Para IV filing based on which USFDA has now granted final approval.

According to IMS data, the US market for generic Oxaliplatin is approximately $ 1.5 billion. Oxaliplatin is part of the oncology portfolio licensed to Pfizer for the US market and the product is available for immediate launch.

Oxaliplatin is a chemotherapy drug used to treat advanced cancer of the colon and rectum. It is used in combination with other medications to slow or stop cancer cell growth.

EP News Bureau

Comments (0)
Add Comment